The effect of combined treatment with phenformin and stanazolol on blood lipids and fibrinolytic activity in patients with hypertriglyceridaemia
- 1 January 1974
- journal article
- research article
- Published by Elsevier in Atherosclerosis
- Vol. 19 (1) , 153-159
- https://doi.org/10.1016/0021-9150(74)90051-3
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- MODE OF ACTION OF PHENFORMIN PLUS ETHYLŒSTRENOL ON FIBRINOLYSISThe Lancet, 1971
- A basic study on the global coagulation and fibrinolysis of hyperlipaemic and atherosclerotic patients: Part 2. Plasminogen activator, plasminogen, α2-Macroglobulin in atherosclerosis and endogenous hypertriglyceridaemiaAtherosclerosis, 1970
- A basic study on the global coagulation and fibrinolysis of hyperlipaemic and atherosclerotic patients: Part 1. The role of atherosclerosis and endogenous hypertriglyceridaemia in global coagulability and fibrinolysisAtherosclerosis, 1970
- Effect of Treatment with Combined Phenformin and Ethyloestrenol on the Coagulation and Fibrinolytic SystemsScandinavian Journal of Haematology, 1970
- Lipid and carbohydrate abnormalities in patients with angiographically documented coronary artery diseaseThe American Journal of Cardiology, 1969
- FIBRINOLYTIC AND DEFIBRINATING EFFECT OF PHENFORMIN PLUS ETHYLŒSTRENOL IN VIVOThe Lancet, 1969
- Enhancement of the Fibrinolytic Activity by Venous Occlusion in Patients with Primary ‘Carbohydrate-Induced’ HypertriglyceridemiaActa Haematologica, 1969
- EFFECT OF ETHYLŒSTRENOL COMBINED WITH PHENFORMIN OR WITH METFORMIN ON PLATELET STICKINESS AND SERUM-CHOLESTEROL IN PATIENTS WITH OCCLUSIVE VASCULAR DISEASEThe Lancet, 1968
- FIBRINOLYTIC ACTIVITY AND CORONARY-ARTERY DISEASEThe Lancet, 1968
- METABOLIC ABNORMALITIES IN PREMATURE CORONARY DISEASE: EFFECTS OF THERAPYAnnals of the New York Academy of Sciences, 1968